TJ Cradick

Company: HuidaGene Therapeutics

Job title: Chief Technology Officer

Seminars:

In-Vitro & In-Vivo Studies to Support the World’s First CRISPR/RNATargeting Therapy, HG202, for Patients with Neovascular Age-Related Macular Degeneration 2:00 pm

Highlight the significant unmet medical need for effective treatments for neovascular age-related macular degeneration Explain the molecular composition, mechanism of action, and preclinical studies of HG202 using animal models Outline the clinical trial design, preliminary safety data, and case studies demonstrating the clinical efficacy of HG202Read more

day: Day Two

Panel Discussion: Comparing Gene Therapy Approaches for Wet AMD: Delivery Methods, Targets, & Therapeutic Potential 3:00 pm

How are intravitreal and subretinal delivery methods impacting treatment precision, effectiveness, and patient experience? What are the implications of targeting VEGF suppression versus complement modulation on efficacy and safety? How can we optimize long-term outcomes by addressing durability, immune response, and safety across different gene therapy approaches?Read more

day: Day Two